Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Solid Tumor Cancer 1Ovarian Neoplasms 1Melanoma 1Lymphoma 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasms × Interleukin-18 × Clear all
NCT00500058 2017-07-26

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

GlaxoSmithKline

Phase 1 Completed
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

NCT00085904 2008-10-13

Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

GlaxoSmithKline

Phase 1 Completed
12 enrolled
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡